A small-molecule MAVS-dependent IRF3 agonist that shows antiviral activity against Flaviviridae, Filoviridae (Ebola virus), Orthomyxoviridae (influenza A virus), Arenaviridae (Lassa virus) and Paramyxoviridae (RSVs, Nipah virus).

A small-molecule probe that selectively kills cells induced to express mutant RAS.

A small-molecule probe that selectively kills cells induced to express mutant RAS.

A small-molecule stabilizer of 14-3-3 protein-protein interactions that stabilizes the complex between 14-3-3 and the stress response regulator GCN1.

A small-molecule stabilizer of p53 mutant Y220C with Kd of 150 uM.

A small-molecule that inhibits Gβγ but not Gα signaling triggered upon activation of Gα(i)-βγ by the chemoattractant receptor OXE-R in both recombinant and human primary cells.

A small-molecule that specifically inhibits the interaction of β-catenin/LEF1 transcriptional complex in colon carcinoma cell lines.

A small-molecule, allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase (TrpAB).

A small-molecule, fumaric acid ester (FAE) compound that is a prodrug of methyl hydrogen fumarate (also known as monomethyl fumarate), for the treatment of relapsing-remitting multiple sclerosis and plaque psoriasis..

A small-molecule, orally active inhibitor of TNF-α that reduces replication of HIV-1 (IC50=300 nM) and Mycobacterium tuberculosis in human cells.

A sodium channel inhibitor..

PF-915275 is a potent and selective inhibitor of human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) (Ki ＜ 1 nM) with good preclinical pharmacokinetic properties.IC50 value: ＜ 1 nM (Ki)[2]Target: 11βHSD1in vitro: PF-915275 maintains potency in our cellular assay against human 11βHSD1 (HEK293, EC50 = 5 nM) and is selective against human 11βHSD2 (HEK293, 1.5% inhibition 10 μM). PF-915275 displays only weak affinity for the rodent choline transporter (Ki = 9.6 μM) and the hamster melatonin MT3 receptor (Ki = 9.6 μM) in the Cerep Bioprint screening panel. PF-915275 has good in vitro pharmacokinetic properties. In particular, PF-915275 is categorized as a low clearance compound (liver microsome assays) with high permeability (Caco2 assay). [2]in vivo: As a prelude to in vivo studies with PF-915275, the rat pharmacokinetic properties of this compound were determined. PF-915275 has an excellent pharmacokinetic profile characterized by low clearance, long half-life and good oral bioavailability. [2]

A specific competitive RIPK1 inhibitor with IC50 of 1.03 uM, 100-fold less potent for RIPK3.

A specific HIF asparaginyl hydroxylase (FIH) inhibitor with Ki of 83 uM, but not HIF prolyl hydroxylase (>1 mM).

A specific inhibitor of MDA-9/Syntenin activity that inhibits MDA-9/Syntenin binding to EGFRvIII.

A specific inhibitor of mitochondrial Na(+)-Ca(2+) exchanger (mNCE) with IC50 of 1.5 uM in INS-1 cells.

A specific p38 MAPK inhibitor with IC50 of 0.6 uM.

A specific small molecule inhibitor of CCR5, inhibits HIV-1 entry..

A specific small molecule inhibitor of CCR5, inhibits HIV-1 entry..

A specific, competitive inhibitor of 14-3-3/ligand interactions with high affinity.

A specific, irreversible inhibitor of MLK-related kinase MRK (ZAK), does not inhibit Bcr-Abl.

A specific, membrane-permeable inhibitor of Gq signaling.